RNA Stock Price, Avidity Biosciences Inc Quote, Chart

Market Summary

USD24.35+0.52

Delayed

2.18%

RNA Alerts

2 major insider sales recently.

RNA Stock Price

View Fullscreen

RNA RSI Chart

RNA Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-9.15

Price/Sales (Trailing)

75.53

Price/Free Cashflow

-15.74

RNA Price/Sales (Trailing)

RNA Profitability

Return on Equity

-42.38%

Return on Assets

-33.76%

Free Cashflow Yield

-6.35%

RNA Fundamentals

RNA Revenue

Revenue (TTM)

25.7M

Rev. Growth (Yr)

17.0K%

Rev. Growth (Qtr)

427.95%

RNA Earnings

Earnings (TTM)

-212.2M

Earnings Growth (Yr)

-19.76%

Earnings Growth (Qtr)

-15.44%

Breaking Down RNA Revenue

Last 7 days

7.1%

Last 30 days

-1.3%

Last 90 days

102.2%

Trailing 12 Months

67.4%

How does RNA drawdown profile look like?

RNA Financial Health

Current Ratio

7.58

RNA Investor Care

Shares Dilution (1Y)

12.59%

Diluted EPS (TTM)

-2.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.4M	10.6M	10.9M	25.7M
2022	7.8M	6.8M	5.9M	5.0M
2021	8.1M	9.2M	9.6M	8.7M
2020	3.7M	5.0M	6.1M	6.8M
2019	0	1.0M	1.7M	2.3M
2018	0	0	0	379.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avidity Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	levin arthur a	acquired	6,200	1.24	5,000	-
Apr 19, 2024	levin arthur a	sold	-114,123	22.8246	-5,000	-
Apr 03, 2024	levin arthur a	sold	-542,214	27.1107	-20,000	-
Apr 02, 2024	boyce sarah	acquired	34,720	1.24	28,000	president and ceo
Apr 02, 2024	boyce sarah	sold	-734,919	26.2471	-28,000	president and ceo
Mar 19, 2024	levin arthur a	acquired	6,200	1.24	5,000	-
Mar 19, 2024	levin arthur a	sold	-119,848	23.9695	-5,000	-
Mar 13, 2024	maclean michael f	sold	-980,760	24.519	-40,000	chief financial officer
Mar 13, 2024	maclean michael f	acquired	352,800	8.82	40,000	chief financial officer
Mar 12, 2024	levin arthur a	sold	-609,017	22.0331	-27,641	-

Which funds bought or sold RNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	nVerses Capital, LLC	new	-	68,904	68,904	0.16%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-4.01	3,995,270	6,336,040	-%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	8,268	12,811	-%
Apr 25, 2024	Aaron Wealth Advisors LLC	sold off	-100	-1,214,890	-	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	30.96	279,500	383,285	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	7,165	11,102	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	280,000	280,000	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	920,000	1,480,000	-%
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	new	-	11,520	11,520	0.01%
Apr 23, 2024	AMALGAMATED BANK	reduced	-59.42	8,000	64,000	-%

Are Funds Buying or Selling RNA?

Are funds buying RNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RNA

No. of Funds

RNA Alerts

2 major insider sales recently.

Unveiling Avidity Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	price t rowe associates inc /md/	12.1%	9,656,852	SC 13G/A
Mar 01, 2024	rtw investments, lp	9.99%	9,659,809	SC 13D/A
Feb 14, 2024	price t rowe associates inc /md/	9.3%	6,917,910	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	3.3%	2,454,533	SC 13G/A
Feb 13, 2024	vanguard group inc	5.46%	4,043,179	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 02, 2024	cowen financial products llc	7.6%	5,628,103	SC 13G/A
Jan 25, 2024	blackrock inc.	8.8%	6,496,593	SC 13G/A
Jan 24, 2024	rtw investments, lp	8.4%	6,701,489	SC 13D/A
Jan 23, 2024	state street corp	4.64%	3,438,328	SC 13G/A

Recent SEC filings of Avidity Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 22, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	S-3ASR	S-3ASR
Mar 21, 2024	4	Insider Trading
Mar 19, 2024	D	D

Peers (Alternatives to Avidity Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Avidity Biosciences Inc News

Latest updates

Avidity Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	427.9%	14,878	2,818	5,771	2,233	87.00	2,482	611	1,795	1,979	2,163	2,607	2,704	2,142	1,746	1,541	1,358	1,445	650	224	-
Operating Expenses	12.2%	68,936	61,443	54,950	59,829	55,994	47,411	48,477	36,255	40,399	31,443	28,974	26,561	18,435	13,212	11,909	7,508	7,492	5,856	4,129	-
S&GA Expenses	17.4%	16,119	13,729	12,278	12,064	10,384	10,094	8,688	8,567	7,431	6,612	6,268	5,884	4,816	3,757	2,925	1,964	1,847	757	1,596	-
R&D Expenses	10.7%	52,817	47,714	42,672	47,765	45,610	37,317	39,789	27,688	32,968	24,831	22,706	20,677	13,619	9,455	8,984	5,544	5,645	5,099	2,533	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	131	78.00	4,338	1,462	1,215	-
Net Income	-15.4%	-60,443	-52,358	-47,025	-52,394	-50,471	-43,599	-45,690	-34,235	-38,538	-29,274	-26,353	-23,844	-16,275	-11,439	-10,556	-6,085	-10,401	-6,668	-5,116	-
Net Income Margin	55.5%	-8.26*	-18.54*	-13.78*	-21.64*	-20.61*	-24.04*	-23.01*	-15.25*	-12.65*	-9.96*	-8.47*	-7.64*	-	-	-	-	-	-	-	-
Free Cashflow	141.5%	15,638	-37,714	-50,429	-50,787	-40,039	-31,852	-36,868	-30,332	-27,922	-21,582	-28,843	-20,206	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	9.7%	629	573	611	614	639	431	421	421	428	426	291	315	334	346	355	97.00
Current Assets	10.0%	611	555	595	597	623	414	404	405	411	422	287	312	332	344	354	96.00
Cash Equivalents	116.1%	185	86.00	154	119	340	144	125	140	321	410	276	301	322	341	352	95.00
Net PPE	3.1%	8.00	8.00	8.00	8.00	6.00	6.00	6.00	5.00	5.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00
Liabilities	129.4%	128	56.00	52.00	55.00	61.00	54.00	46.00	45.00	46.00	31.00	26.00	29.00	28.00	26.00	25.00	28.00
Current Liabilities	65.6%	81.00	49.00	45.00	48.00	52.00	43.00	34.00	31.00	30.00	22.00	16.00	18.00	15.00	14.00	12.00	10.00
Shareholder's Equity	-3.2%	501	517	559	559	578	377	374	376	381	395	264	286	306	320	330	-
Retained Earnings	-11.9%	-570	-510	-458	-410	-358	-308	-264	-218	-184	-146	-116	-90.38	-66.54	-50.26	-38.83	-22.18
Additional Paid-In Capital	4.1%	1,071	1,030	1,020	971	939	689	642	597	566	541	381	376	373	370	369	-43.17
Accumulated Depreciation	-	5.00	-	-	-	3.00	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	7.0%	79.00	74.00	74.00	71.00	70.00	53.00	50.00	48.00	41.00	39.00	38.00	-	-	-	-	-
Float	-	-	-	811	-	-	-	739	-	-	-	798	-	-	-	887	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	144.9%	16,501	-36,791	-49,807	-48,967	-39,189	-31,959	-35,546	-29,574	-26,215	-20,782	-28,135	-19,681	-13,073	-9,113	-7,791	-7,140	-5,019	-5,885	-	-
Share Based Compensation	0.3%	9,845	9,820	9,453	9,104	7,307	7,086	6,508	6,238	4,516	4,550	4,289	3,701	1,878	1,296	687	449	351	22.00	-	-
Cashflow From Investing	262.1%	51,040	-31,479	46,049	-195,680	-7,768	10,932	-17,644	-175,475	-84,064	-800	2,872	-525	-6,930	-845	-	-10.00	-91.00	-14.00	-	-
Cashflow From Financing	79627.5%	31,891	40.00	38,972	22,961	243,654	39,620	38,784	24,113	20,714	155,172	413	17.00	450	-1,346	271,610	1,323	71,824	-712	-	-

RNA Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaboration revenue	$ 9,560	$ 9,224	$ 9,326
Operating expenses:
Research and development	190,968	150,404	101,182
General and administrative	54,190	37,733	26,195
Total operating expenses	245,158	188,137	127,377
Loss from operations	(235,598)	(178,913)	(118,051)
Other income (expense):
Interest income	23,972	4,975	104
Other expense	(594)	(57)	(62)
Total other income (expense)	23,378	4,918	42
Net loss	$ (212,220)	$ (173,995)	$ (118,009)
Net loss per share, basic (in dollars per share)	$ (2.91)	$ (3.34)	$ (2.85)
Net loss per share, diluted (in dollars per share)	$ (2.91)	$ (3.34)	$ (2.85)
Weighted-average shares outstanding, basic (in shares)	73,012	52,162	41,428
Weighted-average shares outstanding, diluted (in shares)	73,012	52,162	41,428
Other comprehensive loss:
Net unrealized gains (losses) on marketable securities	$ 2,823	$ (2,511)	$ (182)
Comprehensive loss	$ (209,397)	$ (176,506)	$ (118,191)

RNA Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 185,082	$ 340,396
Marketable securities	410,269	270,331
Prepaid and other assets	15,956	12,215
Total current assets	611,307	622,942
Property and equipment, net	8,381	6,254
Restricted cash	295	251
Right-of-use assets	8,271	8,755
Other assets	301	598
Total assets	628,555	638,800
Current liabilities:
Accounts payable and accrued liabilities	34,341	32,572
Accrued compensation	14,335	11,190
Lease liabilities, current portion	3,639	3,105
Deferred revenue, current portion	28,365	5,041
Total current liabilities	80,680	51,908
Lease liabilities, net of current portion	6,213	7,582
Deferred revenue, net of current portion	40,898	1,235
Total liabilities	127,791	60,725
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, $0.0001 par value; authorized shares – 400,000; issued and outstanding shares – 79,275 and 69,768 at December 31, 2023 and 2022, respectively	8	7
Additional paid-in capital	1,071,395	939,310
Accumulated other comprehensive income (loss)	125	(2,698)
Accumulated deficit	(570,764)	(358,544)
Total stockholders’ equity	500,764	578,075
Total liabilities and stockholders’ equity	$ 628,555	$ 638,800

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

CEO	Ms. Sarah Boyce
WEBSITE	aviditybiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	186

Avidity Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Avidity Biosciences Inc? What does RNA stand for in stocks?

RNA is the stock ticker symbol of Avidity Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avidity Biosciences Inc (RNA)?

As of Fri Apr 26 2024, market cap of Avidity Biosciences Inc is 1.94 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNA stock?

You can check RNA's fair value in chart for subscribers.

What is the fair value of RNA stock?

You can check RNA's fair value in chart for subscribers. The fair value of Avidity Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avidity Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avidity Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RNA is over valued or under valued. Whether Avidity Biosciences Inc is cheap or expensive depends on the assumptions which impact Avidity Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNA.

What is Avidity Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, RNA's PE ratio (Price to Earnings) is -9.15 and Price to Sales (PS) ratio is 75.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNA PE ratio will change depending on the future growth rate expectations of investors.